Search Browse Earnings

IN8BIO, INC.

Nasdaq:INAB

Biological Products, (No Diagnostic Substances)·NEW YORK, NY

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

IN8BIO, INC. — SlamSEC

Revenue

—

Adj. EBITDA

-$29.0M

FY 2024

Net Income

-$30.0M

FY 2024

EPS (Diluted)

-$1.00

FY 2024

Stock Price

$1.74

+0.0%

2026-03-06

52W Range

$1.17 – $7.86

P/E Ratio

-1.7x

Market Cap

$8.1M

Cash

$21.3M

FY 2024

Total Debt

—

Net Cash

$21.3M

Enterprise Value

-$13.2M

Debt / EBITDA

0.7x

FY 2024

EV / EBITDA

0.5x

Employees

—